Page last updated: 2024-12-04

4-nitrophenol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-nitrophenol: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mononitrophenol : A nitrophenol that is phenol carrying a single nitro substituent at unspecified position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

4-nitrophenol : A member of the class of 4-nitrophenols that is phenol in which the hydrogen that is para to the hydroxy group has been replaced by a nitro group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID980
CHEMBL ID14130
CHEBI ID16836
SCHEMBL ID1839
SCHEMBL ID14501907
SCHEMBL ID13906248
MeSH IDM0083478

Synonyms (113)

Synonym
CHEBI:16836 ,
mononitrophenol
SGCUT00249
phenol,4-nitro
inchi=1/c6h5no3/c8-6-3-1-5(2-4-6)7(9)10/h1-4,8
NPO ,
RPN ,
paranitrofenolo [italian]
ccris 2316
un1663
einecs 202-811-7
caswell no. 603
rcra waste number u170
rcra waste no. u170
epa pesticide chemical code 056301
4-nitrofenol [dutch]
ai3-04856
nsc 1317
paranitrophenol [french,german]
paranitrofenol [dutch]
p-nitrofenol [czech]
hsdb 1157
phenol, p-nitro-
C00870
100-02-7
nsc1317
niphen
wln: wnr dq
paranitrofenolo
para-nitrophenol
p-nitrophenol ,
paranitrofenol
nsc-1317
4-nitrofenol
4-hydroxynitrobenzene
nci-c55992
paranitrophenol
4-nitrophenol
PNP ,
p-hydroxynitrobenzene
phenol, 4-nitro-
4-nitrophenol, reference material
TO_000002
DB04417
4-nitrophenol, spectrophotometric grade
4-nitrophenol, reagentplus(r), >=99%
N-3610
N-3600
p-nitrophenol [un1663] [poison]
BMSE000223
sr-1c2
CHEMBL14130
103427-15-2
4-nitrophenol-15n
N0161
N0220
AKOS000118985
A800004
NCGC00247904-01
NCGC00247904-02
ec 202-811-7
y92zl45l4r ,
unii-y92zl45l4r
p-nitrofenol
NCGC00259993-01
dtxsid0021834 ,
NCGC00254220-01
tox21_202444
dtxcid201834
cas-100-02-7
tox21_300117
N0162
4-nitro-phenol
STL281865
FT-0672814
AE-562/40217722
BP-20405
FT-0600022
EPITOPE ID:161303
paracetamol impurity f [ep impurity]
p-nitrophenol [mart.]
nitrophenol, p-
p-nitrophenol [mi]
4-hydroxy-1-nitrobenzene
4-nitrophenol [hsdb]
1-hydroxy-4-nitrobenzene
S6196
bdbm31678
SCHEMBL1839
3QVU
SCHEMBL14501907
Z57127483
4-nitrophenol-
4- nitrophenol
4-nitryl phenol
4-nitro phenol
p-nitro phenol
SCHEMBL13906248
mfcd00007331
F9995-1636
4-nitrophenol, certified reference material, tracecert(r)
4-nitrophenol, jis special grade, >=99.0%
4-nitrophenol, reagent grade, 98%
4-nitrophenol, pestanal(r), analytical standard
4-nitrophenol, puriss., 99%
4-nitrophenol 10 microg/ml in acetonitrile
4-nitrophenol 100 microg/ml in methanol
o2nc6h4oh
h-m-fluoro-d-phe-omehcl
AS-13146
Q656269
4-nitrophenol,
EN300-18010

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" LD50 values indicate that SS, NAP, and PNP were more toxic (8."( Developmental toxicity of nine selected compounds following prenatal exposure in the mouse: naphthalene, p-nitrophenol, sodium selenite, dimethyl phthalate, ethylenethiourea, and four glycol ether derivatives.
Booth, GM; Bradshaw, WS; Carter, MW; Hardin, BD; Plasterer, MR; Schuler, RL, 1985
)
0.27
" DDTC and disulfiram themselves produced olfactory mucosal lesions in the rat, whereas DDTC protected against the olfactory toxic effects of dichlobenil in the mouse."( Olfactory toxicity of diethyldithiocarbamate (DDTC) and disulfiram and the protective effect of DDTC against the olfactory toxicity of dichlobenil.
Deamer, NJ; Genter, MB, 1995
)
0.29
" One possibility is that Kupffer cells participant in this mechanism since CCl4 elevates calcium, and the release of toxic eicosanoids and cytokines by Kupffer cells is calcium-dependent."( The involvement of Kupffer cells in carbon tetrachloride toxicity.
Edwards, MJ; Kauffman, FC; Keller, BJ; Thurman, RG, 1993
)
0.29
"The safety and toxicity of chemicals given first to animals and finally to humans are generally estimated with a method of safe coefficient, which lacks scientific ground."( [Estimation of safety and toxicity of rho-nitrophenol sodium with a physiologically based pharmacokinetics model].
Gao, Q; Kurihara, N; Wada, O; Yanagisawa, H, 1996
)
0.29
" These results document the ability of rat P450 2E1 to metabolize NDMA to toxic reactive intermediates and demonstrate that this cell line provides a useful model for studying the mechanisms of metabolism-mediated toxicity and carcinogenesis."( Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.
Hollenberg, PF; Lin, HL; Roberts, ES, 1998
)
0.3
"The safety and toxicity of chemicals given first to animals and finally to humans are generally estimated with a method of safe coefficient, which is scientifically a way lack of grounds."( Research on the estimate of safety and toxicity of p-nitrophenol sodium with a physiologically based pharmacokinetics model.
Gao, Q; Kurihara, N; Wada, O; Yanagisawa, H, 1997
)
0.3
"The toxicities of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats was examined and the susceptibility of newborn rats was analyzed in terms of presumed unequivocally toxic and no observed adverse effect levels (NOAELs)."( Comparative study of toxicity of 4-nitrophenol and 2,4-dinitrophenol in newborn and young rats.
Enami, T; Hasegawa, R; Ito, Y; Kamata, E; Koizumi, M; Takano, M; Yamamoto, Y, 2001
)
0.93
" Comparison of EC(50) data obtained with the two methods shows that in both cases 3,5-dichlorophenol is more toxic than other compounds investigated and dichloromethane has a very low toxicity value."( Toxicity assessment of common xenobiotic compounds on municipal activated sludge: comparison between respirometry and Microtox.
Laera, G; Ramadori, R; Ricco, G; Tomei, MC, 2004
)
0.32
" carinata was sensitive to both MP and PNP; however, the parent compound was more toxic than its metabolite."( Acute toxicity of the insecticide methyl parathion and its hydrolytic product p-nitrophenol to the native Australian cladoceran Daphnia carinata.
Cáceres, T; Megharaj, M; Venkateswarlu, K, 2019
)
0.51
" Therefore, it could be concluded that PNP has profound toxic effects on the liver in cellular level."( Long-term exposure to p-Nitrophenol induces hepatotoxicity via accelerating apoptosis and glycogen accumulation in male Japanese quails.
Ahmed, EA; Elsayed, AK; Khaled, HE, 2021
)
0.62
" Its toxic effects on the male reproductive system have been reported, but the underlying mechanisms remain unclear."( Gene expression profiles of two testicular somatic cell lines respond differently to 4-nitrophenol mediating vary reproductive toxicity.
Dong, F; Lu, T; Wei, J; Zhang, C; Zhang, Y, 2021
)
0.85

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies showed that methyl parathion disappeared monoexponentially from plasma and tissues."( Placental transfer and pharmacokinetics of a single dermal dose of [14C]methyl parathion in rats.
Abdel-Rahman, AA; Abou-Donia, MB; Abu-Qare, AW; Kishk, AM, 2000
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
"p-nitrophenol (PNP) was investigated as a model pollutant under the improved UV/Fe3+ process by combination with electrocatalysis."( An improved UV/Fe3+ process by combination with electrocatalysis for p-nitrophenol degradation.
Lei, L; Zhou, M, 2006
)
0.33
"Pulsed discharge plasma (PDP) combined with charcoal (PDP-charcoal) was employed to treat dye wastewater, with methyl orange (MO) as the model pollutant."( Research on dye wastewater decoloration by pulse discharge plasma combined with charcoal derived from spent tea leaves.
Hu, S; Liang, D; Pei, S; Qu, G; Wang, T, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
" After oral administration, peak plasma concentrations were obtained within 3-16 min, and the bioavailability varied from 5 to 71%."( Toxicokinetics of methyl paraoxon in the dog.
Belpaire, F; De Reu, L; De Schryver, E; Willems, J, 1987
)
0.27
" These results indicate that baicalin itself is poorly absorbed from the rat gut, but is hydrolysed to baicalein by intestinal bacteria and then restored to its original form from the absorbed baicalein in the body."( Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form.
Akao, T; Ishihara, K; Kawabata, K; Kobashi, K; Mizuhara, Y; Sakashita, Y; Wakui, Y; Yanagisawa, E, 2000
)
0.31
" In the pharmacokinetic study, PNP was well absorbed dermally, validating the negative dermal carcinogenicity assessment."( Assessment of the genotoxic and carcinogenic risks of p-nitrophenol when it is present as an impurity in a drug product.
Areia, D; Bielawne, J; Bryant, S; Desai-Krieger, D; DeWire, R; Eichenbaum, G; Evans, DC; Guzzie-Peck, P; Johnson, M; Kirkland, D; O'Neill, P; Stellar, S; Tonelli, A; Weiner, S, 2009
)
0.35
"The nonlinear sorption of hydrophobic organic contaminants (HOCs) could be changed to linear sorption by the suppression of coexisting solutes in natural system, resulting in the enhancement of mobility, bioavailability and risks of HOCs in the environment."( Sorption mechanism of naphthalene by diesel soot: Insight from displacement with phenanthrene/p-nitrophenol.
Huang, Y; Lin, D; Wu, W; Yang, K, 2021
)
0.62
" To protect the public's health, screening these pollutants on-site and determining their soil bioavailability is important, but doing so is still challenging."( On-site screening method for bioavailability assessment of the organophosphorus pesticide, methyl parathion, and its primary metabolite in soils by paper strip biosensor.
Li, M; Li, Y; Lu, C; Ma, Z, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Ethoxyresorufin deethylation was induced in the liver by both ethanol treatments, and in the lung the bolus dosing ip increased the activity four-fold."( Influence of ethanol on microsomal p-nitrophenol hydroxylation and ethoxyresorufin deethylation in rat liver and lung.
Carlson, GP, 1991
)
0.28
" In rats dosed with 40 mg/kg, food consumption and growth as well as liver retinol and retinyl palmitate concentrations decreased, while serum retinol and liver weight increased within 28 days following the injection."( Increased retinoic acid metabolism following 3,3',4,4',5,5'-hexabromobiphenyl injection.
Garcin, H; Narbonne, JF; Spear, PA, 1988
)
0.27
" A dose-response study revealed that approximately twice the dose of DDTC was required in mice to cause the same olfactory toxic effects seen in the rat."( Olfactory toxicity of diethyldithiocarbamate (DDTC) and disulfiram and the protective effect of DDTC against the olfactory toxicity of dichlobenil.
Deamer, NJ; Genter, MB, 1995
)
0.29
" Toward gaining sufficient insight into the relevant mechanisms involved in percutaneous absorption of topically applied agents in solution to validate a predictive model, we have 1) estimated porcine stratum corneum/water partition coefficients of two 14C-labeled compounds of interest (phenol and p-nitrophenol), and 2) measured dynamic surface evaporation from dosed excised porcine skin of these two radiolabeled compounds and two 14C-labeled commonly employed vehicles (acetone and ethanol)."( Determination of physicochemical properties of phenol, p-nitrophenol, acetone and ethanol relevant to quantitating their percutaneous absorption in porcine skin.
Brooks, JD; Inman, AO; Monteiro-Riviere, NA; Riviere, JE; Williams, PL, 1994
)
0.29
" A total of 56 8-hr isolated perfused porcine skin flap (IPPSF) topical experiments were used to study the percutaneous absorption and cutaneous distribution of binary mixtures (solute/solvent) of 14C-labeled phenol vs p-nitrophenol (PNP) at two concentrations (4 micrograms/cm2 vs 40 micrograms/cm2) in two vehicles (acetone vs ethanol) under occluded vs nonoccluded dosing conditions."( Quantitative percutaneous absorption and cutaneous distribution of binary mixtures of phenol and para-nitrophenol in isolated perfused porcine skin.
Brooks, JD; Riviere, JE, 1996
)
0.29
" Exposure of the GM2E1 cells to NDMA for 4 days caused severe decreases in cell viability, as determined by crystal violet uptake, and showed a sigmoidal dose-response curve with a median lethal dose of 17 microM."( Heterologous expression of rat P450 2E1 in a mammalian cell line: in situ metabolism and cytotoxicity of N-nitrosodimethylamine.
Hollenberg, PF; Lin, HL; Roberts, ES, 1998
)
0.3
" A three-step dosage regimen was used (72, 144, and 288 micromol of PNP)."( Conjugation of para-nitrophenol by the isolated perfused neonatal sheep liver.
Ching, MS; Ghabrial, H; Gow, PJ; Morgan, DJ; Shulkes, A; Smallwood, RA; Treepongkaruna, S, 2000
)
0.31
" PV dosing resulted in lower total hepatic P450 levels than did JV dosing."( Contribution of direct solvent injury to the dose-dependent kinetics of trichloroethylene: portal vein administration to rats.
Bruckner, JV; Lee, KM; Muralidhara, S; Schnellmann, RG, 2000
)
0.31
" The rate of GI absorption of TCE diminished as the dosage increased."( Mechanisms of the dose-dependent kinetics of trichloroethylene: oral bolus dosing of rats.
Bruckner, JV; Lee, KM; Muralidhara, S; White, CA, 2000
)
0.31
" Female weanling pigs were dosed with [14C]PNP intravenously (150 microg in ethanol, n = 4) or topically onto non-occluded abdominal skin (300 microg/7."( Dermatoxicokinetic modeling of p-nitrophenol and its conjugation metabolite in swine following topical and intravenous administration.
Brooks, JD; Chang, SK; Qiao, GL; Riviere, JE, 2000
)
0.31
"5 h after dosing and was in descending order: kidney 23."( Placental transfer and pharmacokinetics of a single oral dose of [14C]p-nitrophenol in rats.
Abou-Donia, MB; Abu-Qare, AW; Brownie, CF, 2000
)
0.31
" The trend of the variation of the k(d) values with the dosages of PAC or PRH used suggests that higher rate of bioregeneration can be achieved under non-excess adsorbent dosage condition."( Bioregeneration of activated carbon and activated rice husk loaded with phenolic compounds: Kinetic modeling.
Lim, PE; Ng, SL; Seng, CE, 2010
)
0.36
" Also, the effect of the kinds of catalyst, temperature, pH, initial concentration, and dosage of catalyst on the efficiency of 4-NP degradation was investigated."( High efficiency degradation of 4-nitrophenol by microwave-enhanced catalytic method.
Chen, JH; Lai, TL; Shu, YY; Wang, CB; Yong, KF; Yu, JW, 2011
)
0.66
"1, H(2)O(2) dosage 83."( Heterogeneous Fenton-like catalytic removal of p-nitrophenol in water using acid-activated fly ash.
Jiang, P; Liu, G; Wang, N; Zhang, A; Zhou, J, 2012
)
0.38
" Compared with conventional anaerobic process, the cosubstrate dosage in BES was significantly reduced due to the high coulombic efficiencies at the cathode."( Bioelectrochemical system for recalcitrant p-nitrophenol removal.
Feng, C; Han, W; Jia, F; Li, J; Mu, Y; Shen, J; Sun, X; Wang, L; Zhang, Y, 2012
)
0.38
" However, after a long PNP starvation period the only experiment still showing total PNP removal during a second PNP shock load was the one where a dosage of 5% w/w was applied."( Bioaugmentation for treating transient or continuous p-nitrophenol shock loads in an aerobic sequencing batch reactor.
Carrera, J; Martín-Hernández, M; Suárez-Ojeda, ME, 2012
)
0.38
" The experiment parameters like pH, external resistance, limonite dosage and initial PNP concentration were investigated in this research."( Degradation of p-nitrophenol in a BES-Fenton system based on limonite.
Lei, T; Tao, HC; Wei, XY; Xu, N; Zhang, LJ, 2013
)
0.39
" SO4(2-) species and its dosage have markedly inhibitory effect on p-NP reduction due to the selective adsorption of SO4(2-) and the formation of sulphated surface complexes on the fresh Fe hydroxide."( Reductive transformation of p-nitrophenol by Fe(II) species: the effect of anionic media.
Chen, R; Geng, L; Wang, X; Wei, Y; Wu, D; Wu, Y, 2013
)
0.39
" More importantly, the required dosage of organic cosubstrate was significantly reduced in the UASB-BES system than that in the UASB reactor."( Coupling of a bioelectrochemical system for p-nitrophenol removal in an upflow anaerobic sludge blanket reactor.
Hua, C; Jiang, X; Li, J; Mu, Y; Shen, J; Sun, X; Wang, L; Xu, X; Zhang, L, 2014
)
0.4
" The effect of key operating parameters such as ferrihydrite dosage, initial solution pH and H2O2 dosage were also studied on the photocatalytic degradation of p-nitrophenol."( Photo-catalyzed p-nitrophenol degradation in aqueous dispersions of ferrihydrite and H2O2.
Chen, R; Liu, H; Wei, Y; Wu, D; Wu, Y, 2014
)
0.4
" Out of 10(7) variants of PobR, four were active when dosed with pNP, with two mutants showing a specificity switch from the native effector 4-hydroxybenzoate (4HB)."( A microbial sensor for organophosphate hydrolysis exploiting an engineered specificity switch in a transcription factor.
Jedrzejczak, R; Jha, RK; Joachimiak, A; Kern, TL; Kim, Y; Strauss, CE; Tesar, C, 2016
)
0.43
"PN1 can survive in soils contaminated with PNP dosage between 90 and 155 mg/kg and considerably improved the removal PNP efficiency in soils."( Pseudomonas monteilii PN1: a great potential P-nitrophenol degrader with plant growth promoting traits under drought and saline-alkali stresses.
Liu, J; Mu, W; Ren, H; Wang, Y; Yang, F; Zhang, Y, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
4-nitrophenolsA mononitrophenol that is 4-nitrophenol and its derivatives resulting from substitution of one or more of the hydrogens attached to the benzene ring by a non-nitro group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase II - Conjugation of compounds73122
Cytosolic sulfonation of small molecules1747

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
acetylcholinesteraseHomo sapiens (human)Potency75.62760.002541.796015,848.9004AID1347395; AID1347397; AID1347399
RAR-related orphan receptor gammaMus musculus (house mouse)Potency36.66860.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency17.60540.000221.22318,912.5098AID743035; AID743036; AID743053
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency32.76850.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency2.52800.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency56.59480.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency64.31250.001530.607315,848.9004AID1224848; AID1224849; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency40.68340.000229.305416,493.5996AID1259244; AID743069; AID743075; AID743078
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency76.95880.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.389019.739145.978464.9432AID1159509
histone deacetylase 9 isoform 3Homo sapiens (human)Potency30.09510.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency40.06610.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency44.95490.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency40.06610.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Sulfotransferase 1A1Homo sapiens (human)Ki283.000038.0000160.5000283.0000AID977610
Chain A, Sulfotransferase 1A1Homo sapiens (human)Ki283.000038.0000160.5000283.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
EndolysinTequatrovirus T4Kd63.00003.00003.00003.0000AID728448; AID728450
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucuronosyltransferase 1A4Homo sapiens (human)Km11,600.00007.00007.00007.0000AID214939
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (128)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
bilirubin conjugationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
heme catabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
cellular glucuronidationUDP-glucuronosyltransferase 1A4Homo sapiens (human)
vitamin D3 metabolic processUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
retinoic acid bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
glucuronosyltransferase activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
enzyme bindingUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein homodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
protein heterodimerization activityUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (21)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulum membraneUDP-glucuronosyltransferase 1A4Homo sapiens (human)
endoplasmic reticulumUDP-glucuronosyltransferase 1A4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (87)

Assay IDTitleYearJournalArticle
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID624607Specific activity of expressed human recombinant UGT1A32000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1145622Uncoupling of oxidative phosphorylation in rat liver mitochondria at pH 6 relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID577298Metabolic stability in rat liver microsomes assessed as half life by LC-MS/MS analysis2011Journal of medicinal chemistry, Feb-24, Volume: 54, Issue:4
2-Aminothiazoles as therapeutic leads for prion diseases.
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1145618Octanol-aqueous phase distribution coefficient, log D of the compound at pH 61977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID266764Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID23255Partition coefficient (logP) (ether)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID26793Partition coefficient (logP)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1145617Octanol-aqueous phase distribution coefficient, log D of the compound at pH 51977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID282838Cytotoxicity against human CCRF-CEM cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1145624Uncoupling of oxidative phosphorylation in rat liver mitochondria at pH 8 relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID624611Specific activity of expressed human recombinant UGT1A82000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1304850Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of tiron2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID25611Dissociation constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID266765Effective permeability coefficient in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1304848Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of Cu2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266767Membrane retention in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID728449Binding affinity to Enterobacteria phage T4 lysozyme L99A mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID266769Membrane retention in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1304847Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of tiron2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID727731Dissociation constant, pKa of the compound at pH 3 to 12 by UV spectroscopy2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Rapid Determination of Ionization Constants (pK a) by UV Spectroscopy Using 96-Well Microtiter Plates.
AID728443Binding affinity to Enterobacteria phage T4 lysozyme harboring L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 1 mM at pH 6.8 by circular dichroism analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID624616Specific activity of expressed human recombinant UGT2B152000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266768Membrane permeability, CA(t)/CD(0) in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID728446Selectivity ratio of Kd for Enterobacteria phage T4 lysozyme L99A/M102Q double mutant to Kd for Enterobacteria phage T4 lysozyme L99A/M102H double mutant2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID282835Cytotoxicity against mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID303044Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID26261Partition coefficient (logD7.2)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID23252Partition coefficient (logP) (benzene)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID158632Compound was tested for the inhibitory activity against cobra venom PLA2 (Naja naja atra) by using the Dole assay1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The structure-activity relationships of a series of suicide inhibitors of phospholipase A2.
AID728450Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID23251Partition coefficient (logP)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID282839Cytotoxicity against human CEM/VLB cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID40936Inhibition of Bacillus subtilis PCI219 spore germination, expressed as log 1/I501982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID282833Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID15680Partition coefficient (logP)1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID159270Toxicity determined using Microtox Test1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Using theoretical descriptors in quantitative structure-activity relationships: some toxicological indices.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID23256Partition coefficient (logP) (hexane)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID303043Cytotoxicity against human MIA PaCa2 cells after 4 hrs by MTT assay2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.
AID728448Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102Q double mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID1304852Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of Fe2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1145621Uncoupling of oxidative phosphorylation in rat liver mitochondria at pH 5 relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266763Membrane retention in 70% silicon-30% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID266770Membrane permeability, CA(t)/CD(0) in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID681153TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Chemical research in toxicology, Dec, Volume: 14, Issue:12
Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.
AID23253Partition coefficient (logP) (carbon tetrachloride)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID19255Partition coefficient (logP)1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266760Permeability coefficient in silicon membrane using diffusion cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID310932Permeability across human Skin2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID158633Apparent rate constant against phospholipase A2 enzyme inactivation by using pseudo first-order kinetics was evaluated1998Bioorganic & medicinal chemistry letters, Aug-18, Volume: 8, Issue:16
The structure-activity relationships of a series of suicide inhibitors of phospholipase A2.
AID728444Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102H double mutant expressed in Escherichia coli BL21(DE3) assessed as change in melting temperature at 1 mM at pH 5.4 by circular dichroism analysis2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID1145623Uncoupling of oxidative phosphorylation in rat liver mitochondria at pH 7 relative to control1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID266771Permeability in human skin2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1462355Drug metabolism in rat liver microsomes assessed as p-nitrocatechol formation after 60 mins
AID1304849Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of Fe2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID282834Activity against caspase-mediated apoptosis in mouse L1210 cells2005Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23
Cellular apoptosis and cytotoxicity of phenolic compounds: a quantitative structure-activity relationship study.
AID624619Specific activity of expressed human recombinant UGT2B72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266762Effective permeability coefficient in 100% IPM membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1145606Octanol-aqueous phase partition coefficient, log P of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID266761Effective permeability coefficient in 100% silicon membrane2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID237685Lipophilicity determined as logarithm of the partition coefficient in the alkane/water system2005Journal of medicinal chemistry, May-05, Volume: 48, Issue:9
Calculating virtual log P in the alkane/water system (log P(N)(alk)) and its derived parameters deltalog P(N)(oct-alk) and log D(pH)(alk).
AID19254Partition coefficient of compound was measured in heptane/water system1993Journal of medicinal chemistry, Nov-26, Volume: 36, Issue:24
Solvent-dependent conformation and hydrogen-bonding capacity of cyclosporin A: evidence from partition coefficients and molecular dynamics simulations.
AID23254Partition coefficient (logP) (chloroform)1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
The role of solvent-accessible surface area in determining partition coefficients.
AID1145614Dissociation constant, pKa of the compound1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1304854Aqueous solubility of compound in media after 16 hrs2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID214939Binding affinity against human UDP Glucuronosyltransferase 1A4 (UGT1A4)2003Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9
Pharmacophore and quantitative structure-activity relationship modeling: complementary approaches for the rationalization and prediction of UDP-glucuronosyltransferase 1A4 substrate selectivity.
AID624617Specific activity of expressed human recombinant UGT2B172000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID266766Dissociation constant, pKa of the compound2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability.
AID1304861Dissociation constant, pKa of compound2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID728447Binding affinity to Enterobacteria phage T4 lysozyme L99A/M102E double mutant expressed in Escherichia coli BL21(DE3) by isothermal titration calorimetry2013Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7
The impact of introducing a histidine into an apolar cavity site on docking and ligand recognition.
AID1145619Octanol-aqueous phase distribution coefficient, log D of the compound at pH 71977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1304851Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of Cu2+2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID40623Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1304853Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method2016Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8
Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1145620Octanol-aqueous phase distribution coefficient, log D of the compound at pH 81977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Use of distribution coefficients in quantitative structure-activity relationships.
AID1524436Substrate activity at recombinant Haemophilus influenzae Chloramphenicol nitroreductase expressed in Escherichia coli assessed as initial rate of reaction at 150 uM measured at 30 sec interval for 5 mins in presence of NADPH at pH 8 under 37 degC by UV-vi2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Investigating the promiscuity of the chloramphenicol nitroreductase from Haemophilus influenzae towards the reduction of 4-nitrobenzene derivatives.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2011Journal of molecular biology, Aug-26, Volume: 411, Issue:4
Directed evolution of sulfotransferases and paraoxonases by ancestral libraries.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,466)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990177 (12.07)18.7374
1990's229 (15.62)18.2507
2000's325 (22.17)29.6817
2010's565 (38.54)24.3611
2020's170 (11.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 120.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index120.36 (24.57)
Research Supply Index7.33 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index224.75 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (120.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.07%)5.53%
Reviews6 (0.39%)6.00%
Case Studies2 (0.13%)4.05%
Observational0 (0.00%)0.25%
Other1,511 (99.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]